文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

慢性偏头痛的管理

Management of chronic migraine.
PubMed 文献 · BMJ · 2022-10-10

本文综述慢性偏头痛的流行病学、诊断标准与危险因素,讨论循证药物与非药物治疗的优劣及以患者为中心的照护原则,并涉及鉴别诊断、共病、临床推理、启动与监测、成本与可及性。文章还讨论国际指南、行为与补充疗法及生活方式调整,以及儿科、妊娠和老年人等特殊人群的管理与未来研究方向。

要点

  • 过去五年慢性偏头痛治疗显著扩展,包括降钙素基因相关肽拮抗剂和神经调控设备。
  • 综述涵盖药物与非药物治疗的循证证据、优劣及以患者为中心的照护原则。
  • 管理需关注鉴别诊断、共病、临床推理、治疗启动与监测、成本及可及性。

核心结论

  • 慢性偏头痛是与显著残疾、生产力丧失和全球巨大经济负担相关的神经系统疾病,近五年治疗选择显著扩展。

研究设计与样本

  • 综述,涵盖慢性偏头痛的流行病学、诊断标准、危险因素、药物与非药物治疗、国际指南及特殊人群管理。

主要发现

  • 过去五年慢性偏头痛治疗显著扩展,包括降钙素基因相关肽拮抗剂和神经调控设备。
  • 综述讨论了药物与非药物治疗的证据、优劣及以患者为中心的照护原则,并关注鉴别诊断、共病、临床推理、启动与监测、成本与可及性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic migraine is a neurologic disorder associated with considerable disability, lost productivity, and a profound economic burden worldwide. The past five years have seen a dramatic expansion in new treatments for this often challenging condition, among them calcitonin gene related peptide antagonists and neuromodulatory devices. This review outlines the epidemiology of and diagnostic criteria and risk factors for chronic migraine. It discusses evidence based drug and non-drug treatments, their advantages and disadvantages, and the principles of patient centered care for adults with chronic migraine, with attention to differential diagnosis and comorbidities, clinical reasoning, initiation and monitoring, cost, and availability. It discusses the international guidelines on drug treatment for chronic migraine and evaluates non-drug treatments including behavioral and complementary therapies and lifestyle modifications. Finally, it discusses the management of chronic migraine in special populations, including pediatrics, pregnancy, and older people, and considers future questions and emerging research in the field.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Hovaguimian A, Roth J. Management of chronic migraine. BMJ. 2022. PMID: 36216384. doi:10.1136/bmj-2021-067670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。